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S U M M A R Y
Objective: To evaluate the efﬁcacy of ivermectin and combined ivermectin–metronidazole therapy in the
treatment of ocular and skin lesions of Demodex folliculorum.
Methods: One hundred twenty patients with skin lesions and anterior blepharitis, whose infestation was
treatment-resistant and who had a Demodex count >5 mites/cm2 for skin lesions or 3 mites at the root
of each eyelash, were recruited. The treatment regimens were ivermectin and ivermectin–
metronidazole combined therapy. We enrolled 15 patients from each of four groups for each treatment
regimen. Demodex was detected by standardized skin surface biopsy for skin lesions. Three eyelashes
from each affected lower eyelid were epilated and examined. The study subjects were followed-up once
a week for four visits.
Results: There was a difference in the mite count between the subgroups taking ivermectin and
combined therapy during all follow-up visits. At the last visit, in the combined therapy subgroup, 1.7% of
patients showed no clinical improvement, 26.7% showed a marked clinical improvement, and 71.6%
showed complete remission. In those on the ivermectin regimen, 27 patients had a mite count >5 mites/
cm2, 21.7% showed no clinical improvement, 33.3% showed a marked improvement, and 45% showed
complete remission.
Conclusions: Combined therapy was superior in decreasing the D. folliculorum count in all groups and in
reducing the mite count to the normal level in rosacea and in anterior blepharitis. On the other hand, the
two regimens were comparable in reducing the mite count to the normal level in acne and peri-oral
dermatitis lesions.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Demodex folliculorum is the most common ectoparasite of man.1
It is an elongated transparent worm-like parasite with an obvious
head, neck, and a body-tail part, of which the former has four pairs
of stumpy legs measuring about 0.35–0.4 mm in length; it has
protruding stumpy sharp mouth parts.2Infestation with this
organism may play a role in many clinical entities, such as
rosacea-like demodicosis,3 pustular folliculitis,4,5 papulo-pustular
scalp eruptions,6 peri-oral dermatitis,7 and hyperpigmented
patches of the face.8 In the ﬁeld of ophthalmology, Demodex spp
are thought to play a role in the etiology of blepharitis, chronic* Corresponding author. Tel.: +20 173811104.
E-mail address: dr_doaasalem@yahoo.com (D.A.B. Salem).
1201-9712/$36.00 – see front matter  2012 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2012.11.022eczematous blepharitis (blepharitis acarica), madarosis (loss of
eyelashes), and treatment-resistant chronic blepharitis.9–12
Ivermectin is a safe and effective orally administered antipara-
sitic drug. Its selective activity against human parasites is due to its
high afﬁnity for glutamate-gated chloride ion channels found in
the peripheral nervous system of invertebrates; it does not readily
cross the mammalian blood–brain barrier, where ligand-gated
chloride ion channels are found in mammals, hence humans are
spared from adverse central nervous system effects of the drug.13
The binding of ivermectin to this ion channel in the nerve and
muscle cells results in increased permeability of the cell membrane
to chloride ions, leading to hyperpolarization with subsequent
paralysis and death of the parasite.14
The acaricidal effect of metronidazole on the Demodex mite
is not known. It has been proposed that metronidazole may act
on the mite via one or more of its active metabolites formed in
vivo.15ses. Published by Elsevier Ltd. All rights reserved.
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and combined ivermectin–metronidazole therapy in the treat-
ment of refractory anterior blepharitis and skin lesions of
D. folliculorum.
2. Methods
2.1. Study design
This was a randomized, single-blind, controlled clinical trial,
comparing the efﬁcacy of ivermectin and combined therapy with
ivermectin–metronidazole in the treatment of anterior blepharitis
and skin lesions of D. folliculorum.
2.2. Participants
This study took place in the Dermatology and Ophthalmology
Clinic of the Mansoura University Hospitals between June 2011
and February 2012.
One hundred twenty patients were enrolled (mean age
36.71  12.4 years) and categorized into four groups of 30 patients
each (patients with acne vulgaris, rosacea, peri-oral dermatitis, and
anterior blepharitis).
The selection criteria for patients with skin lesions were: a
treatment-resistant infestation, with D. folliculorum mite density
>5 mites/cm2.
The potential criteria for the diagnosis of Demodex blepharitis
are summarized as follows:16 (1) clinical history: high index of
suspicion when blepharitis is refractory to conventional treat-
ments, or when there is madarosis or recurrent trichiasis; (2) slit-
lamp examination: typical cylindrical dandruff at the root of
eyelashes; (3) microscopic conﬁrmation: detection and counting of
Demodex mites in epilated lashes.
Patients with a mite density 5 mites/cm2 for skin lesions or
with <3 living mites/eyelash, a history of systemic or topical
antibacterial or anti-inﬂammatory drugs in the 60 days before
study entry, those with a known hypersensitivity to ivermectin or
metronidazole, and pregnant women were excluded. In patients
with anterior blepharitis, we also excluded those with posterior or
mixed blepharitis, contact lenses, meibomian gland dysfunction,
and any previous eye surgery.
2.3. Ethics issues
Informed consent was obtained from each of the participants,
and the study was performed in accordance with the principles of
our institutional ethics committee.
2.4. Sample size calculation
At the time this study was designed there were insufﬁcient
data to perform a reliable sample size calculation. So we
anticipated that two groups of 60 patients each would be
sufﬁcient to indicate efﬁcacy of the two regimens at 4 weeks.
Based on the outcome of this pilot study, we will design a larger
randomized controlled trial, including a large number of patients,
based on a power calculation.
2.5. Randomization and blinding
The 120 participants were randomly assigned to either
combined therapy or ivermectin treatment at a ratio of 1:1
(15 patients for each treatment regimen from each group) using a
computer-generated randomization schedule. The assignment was
done in a single-blinded manner, in which the subjects were
blinded to the treatment assignment.2.6. Hypothesis
Since metronidazole has an anti-inﬂammatory and acaricidal
action, it is expected to have a better effect in combination with
ivermectin and improve the outcome of treated patients.
2.7. Intervention
In each group 15 patients received combined therapy with
metronidazole (does 250 mg three times per day for 2 weeks) and
ivermectin (two doses of 200 mg/kg, 1 week apart), and 15 patients
received ivermectin alone (two doses of 200 mg/kg, 1 week apart).
All patients were then followed-up weekly for four visits.
2.8. Outcome measurements
For skin lesions, a standardized skin surface biopsy was
performed for the detection of D. folliculorum in lesion areas.
Subjects brieﬂy washed their faces with a bland soap and water
and then put on a pair of safety goggles. A drop (about 0.05 ml) of
cyanoacrylate glue (Krazy Glue) was applied to one end of a plastic
slide (1  3 inch plastic slides) and spread out to a uniform
thickness using the nozzle of the Krazy Glue bottle. The slide was
then pressed against a lesion area causing the glue to spread to a
thin ﬁlm the width of the slide (1 inch) and approximately half its
length (1.5 inch). The slide was left in place for 5 min while the
cyanoacrylate hardened as it polymerized. Initially a standard
surface area of 1 cm had been drawn on the other side of the slide
with a waterproof marker; the area of 1 cm was divided into four
equal squares in order to make counting of the parasite easier after
removal of the slide.17
For the detection of Demodex in anterior blepharitis, under a
slit-lamp biomicroscope three eyelashes from each lower eyelid
were epilated with ﬁne forceps. Eyelashes were placed on a glass
slide and mounted with a cover slip. Epilated eyelashes and skin
samples were clariﬁed with two to three drops of immersion oil
and examined microscopically at standard magniﬁcations (40
to  100) as soon as possible (within 2–4 h), as the movement of
mites decreases with time and they may even disintegrate.18 For
eyelashes, determination of 3 living parasites at the root of each
eyelash was diagnosed as infestation. The Demodex count was
recorded as the total number of mites found in a total of three
lashes per eye. For the diagnosis of a skin sample infestation, >5
living parasites in an area 1 cm2 was required.19 Patients were
assessed prior to randomization and weekly for 1 month
throughout the study.
The outcome measurements were done at the last visit. The
primary outcome was a decrease in mite density for each
treatment (5 mites/cm2 for skin lesions and <3 living mites/
eyelash). Secondary outcomes were clinical improvements in
itching, burning, redness, and scaling at the root of the lashes in
anterior blepharitis patients, and improvements in erythema,
dryness, scaling, roughness, and/or papules/pustules in skin
lesions.
Assessment of the outcome samples was done by two
unblinded parasitologists and then reviewed by another indepen-
dent blinded professor of parasitology to avoid bias.
2.9. Statistical analysis
Data entry and analysis were all done using SPSS software
version 17 (Chicago, IL, USA). Results were expressed as mean 
standard deviation (SD), or number (%). Comparisons between the
mean values were done using the independent sample t-test and
Mann–Whitney test. The Chi-square test was used to compare the
primary outcome in ivermectin and combined regimens and for
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conﬁdence interval (95% CI) for the difference between independent
proportions was calculated by the Wilson with continuity correction
method. A p-value of <0.05 was considered statistically signiﬁcant.
3. Results
3.1. Patient characteristics
One hundred twenty eligible patients were enrolled in this
study; no patient missed any follow-up visit or discontinued
treatment. Sixty patients were allocated to receive ivermectin and
60 to receive the combined therapy.
Baseline characteristics of the patients in each group are
summarized in Table 1.
3.2. Efﬁcacy
In the cases who received ivermectin alone, there was a gradual
reduction in the mean follicle mite count at the ﬁrst week visit
(Table 2). However, rebound elevation in the mite count was
evident in the third week in some patients with rosacea and those
with anterior blepharitis lesions (Table 2).
In the combined therapy subgroup, the mean counts of
Demodex were dramatically reduced in all patients within 1 week
(Table 2).
In comparing the efﬁcacy of the two regimens, we demonstrat-
ed that the combined therapy was superior in decreasing the mean
count of D. folliculorum in all groups (p < 0.05) (Table 2) and in
reducing the mite count to a normal level in rosacea (mite density
5 mites/cm2) (p < 0.001; 95% CI 0.4–0.9) (Figure 1; Table 3) and in
blepharitis (<3 mites/eyelash) (p = 0.002; 95% CI 0.2–0.8)
(Figure 2; Table 3). The two regimens were comparable in terms
of the reduction in mite count to a normal level in the acne group
(p = 0.1; 95% CI 0.04–0.6) (Figure 3; Table 3) and peri-oral
dermatitis group (p = 0.5; 95% CI 0.1–0.4) (Figure 4; Table 3)
(mite density 5 mites/cm2).
With regard to clinical improvement, at the last visit for those
on the combined therapy regimen, 1.7% of patients showed no
clinical improvement, 26.7% showed a marked clinical improve-
ment, and 71.6% showed complete remission, while in those on the
ivermectin regimen, 27 patients had a mite count >5 mites/cm2,
21.7% of them showed no clinical improvement, 33.3% showed a
marked improvement, and 45% showed complete remission.
At the end of the follow-up, one case on the combined therapy
regimen had an infestation that continued to be treatment-
resistant (the mites were persistent in their lesions) and after
histopathological examination of the lesion, the case was
diagnosed as lupus miliaris disseminatus faciei (LMDF).Table 1
Age, gender, and Demodex mite density among studied groups
Age, years, mean  SD Gender 
Female, n (%
Acne group
Ivermectin 34.9  13.9 10 (66.7%) 
Combined 32.5  9.9 12 (80%) 
Rosacea group
Ivermectin 32.4  9 12 (80%) 
Combined 35.9  8.3.1 8 (53.3%) 
Peri-oral dermatitis group
Ivermectin 43.7  15.9 4 (26.7%) 
Combined 36.8  11.5 10 (66.7%) 
Blepharitis group
Ivermectin 38.4  15.8 5 (33.3%) 
Combined 38.6  10.9 3 (20%) 
SD, standard deviation.4. Discussion
There are no standardized therapeutic recommendations for
the treatment of demodicidosis. Although topical therapy alone is
often not sufﬁciently effective, many reports have been written on
the use of topical medications like lindane,20 metronidazole,21
benzyl benzoate,19 permethrin,22 hexachlorocyclohexane,23 and
camphor oil.24 Few reports have been written on the systemic
medications, e.g., oral ivermectin.22,25 Hence the purpose of this
study was to evaluate the therapeutic and clinical outcomes of the
oral administration of an ivermectin regimen compared with
combined ivermectin and metronidazole in the treatment of
D. folliculorum-associated anterior blepharitis and skin lesions.
In the present work, during the ﬁrst week of follow-up, no
obvious change in the mite count was observed in all the groups
receiving ivermectin, while through the third week, a rebound
elevation in the mite count was observed in some cases in the
rosacea and anterior blepharitis groups. However, in the fourth
week there was a decrease in mite counts in all the studied groups.
These results agree with those of Holzchuh et al.,26 who
observed a signiﬁcant improvement in the absolute number of
D. folliculorum in the eyelashes after treatment with oral
ivermectin.
Also, Baima and Sticherling27 used oral ivermectin for skin
lesions caused by Demodex, in combination with 4% pilocarpine
gel in blepharitis, and reported a statistically signiﬁcant reduction
in the number of mites after treatment. Neither study pointed to a
reduction in the mite count to the normal level after the
administration of oral ivermectin in any of the studied cases.
These results, together with our results, strongly infer that an
ivermectin regimen alone cannot eradicate a Demodex infection
but only reduce the number of mites.
There are few reports on systemic metronidazole therapy for
D. folliculitis. Studies on oral metronidazole alone for the
treatment of Demodex skin lesions have shown a marked
reduction in the inﬂammatory picture, but not of the Demodex
population.28,29 However in the study of Schaller et al.,30 therapy
with the oral administration of 250 mg metronidazole three
times a day for 2 weeks resulted in a rapid and lasting recovery.
Subsequent follow-up evaluation for the next 9 months showed
excellent control of the disease. Repeated scrapings remained
negative for D. folliculorum mites.
Other studies have reported complete recovery, with the
disappearance of facial mites in treatment with combinations of
oral and topical metronidazole; in a case of fulminant rosacea-like
eruption with multiple D. folliculorum mites,21 Grossmann et al.31
used 750 mg/day metronidazole for 3 weeks in conjunction with
100 mg/day prednisolone, topical 2% metronidazole, and 0.15%
lindane emulsion, and in a study by Anane et al.,32 the patient wasDemodex density, mean  SD
) Male, n (%)
5 (33.3%) 12.3  3.2
3 (20%) 12.9  6.1
3 (20%) 51.7  20.8
7 (46.7%) 51.5  26.3
11 (73.3%) 21.3  7.5
5 (33.3%) 21.9  6.8
10 (66.7%) 12.8  6.8
12 (80%) 15  5.7
Table 2
Comparing mite density of studied groups before treatment and through follow-up visits, using different therapy regimens
Mite density Acne, mean  SD Rosacea, mean  SD Peri-oral dermatitis, mean  SD Blepharitis, mean  SD
Pre-therapy
Ivermectin 12.3  3.2 51.7  20.8 21.3  7.5 12.8  6.8
Combined 12.9  6.1 51.5  26.3 21.9  6.8 15  5.7
Mean difference (95% CI) 0.6 (4.2–3) 0.3 (17.5–18) 0.6 (5.69–4.8) 2.2 (6.9–2.5)
p-Value 0.9 0.98 0.9 0.187
1st week
Ivermectin 12.1  3.2 50.5  20.3 21.1  7.6 12.6  6.9
Combined 8.4  5.1 37.7  18.9 13.4  4.9 7.6  4.7
Mean difference (95% CI) 3.6 (0.4–6.8) 12.8 (1.9–27.5) 7.7 (2.9–12.5) 5 (0.5–9.5)
p-Value 0.02 0.04 0.009 0.04
2nd week
Ivermectin 8.4  2.6 41.1  15.8 10.5  3.9 8. 5  7.6
Combined 5.6  4.6 25.9  22.6 5.8  3.4 2.5  2.9
Mean difference (95% CI) 2.8 (0.03–5.6) 15.2 (0.6–29.8) 4.7 (2–7.5) 5.9 (1.6–10.2)
p-Value 0.04 0.016 0.005 0.003
3rd week
Ivermectin 5.3  2.4 41.9  21.4 5.2  2.9 8.5  6.3
Combined 2.1  3.2 12.5  25.6 1.3  1.2 1  1.7
Mean difference (95% CI) 3.3 (1.2–5.4) 29.4 (11.7–47.1) 3.9 (2.3–5.6) 7.5 (4.1–11)
p-Value 0.006 0.001 <0.001 <0.001
4th week
Ivermectin 2.3  2.7 31.4  18.9 1.7  1.7 5.3  5.4
Combined 0.5  1.2 5.5  19.5 0.2  0.4 0.2  0.4
Mean difference (95% CI) 1.8 (0.2–3.4) 25.9 (11.5–40.3) 1.6 (0.5–2.7) 5.1 (2.3–8)
p-Value 0.02 0.001 0.003 <0.001
SD, standard deviation; CI, conﬁdence interval; p-value, probability of error.
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mercury ointment for 15 days. The facial mites disappeared and
there was complete remission without recurrence.
Although this combination regimen has not been studied
before, we found that in the combined therapy regimen, there was
a reduction in the mite count from the ﬁrst week and through the
follow-up visits. With regard to the reduction in the mite count to
the normal level, only one case continued to resist treatment, and
after a histopathological examination the case was diagnosed as
LMDF.
By comparing both regimens in terms of the decrease in mite
count, we found that the reduction with combined therapy was
statistically higher than that for ivermectin alone in all the studied
groups. In addition, the combined regimen was signiﬁcantly better
at reducing the mite count to the normal level in the rosacea and
anterior blepharitis groups.
The obvious improvement in the clinical picture in the
subgroups receiving the combined therapy may be attributed to
the fact that the mite D. folliculorum antigens could generate an
immune response leading to the inﬂammatory changes. Since0
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Figure 1. Mite density of rosacea group before treatment and through follow up
visits using different regimen therapy.metronidazole is particularly effective against the inﬂammatory
papulo-pustular component of the disease, its mechanism of action
may involve an anti-inﬂammatory effect. Evidence has been
presented that metronidazole has a direct pharmacological effect
on anti-inﬂammatory inﬂuences on T lymphocytes,33 and further,
alterations in neutrophil cell function have been shown, inhibiting
the generation of reactive oxygen species. Other investigators have
provided evidence of an anti-inﬂammatory activity.28 In addition
metronidazole may have acaricidal activity, as it is degraded in
vivo into at least ﬁve metabolites with potent biological activity
(e.g., its 2-hydroxymethyl derivative is one-third- to 10-times
more active as an antibacterial agent than metronidazole itself).15
So, we suggest that the combined therapy works better than
ivermectin alone on cases with different skin lesions and anterior
blepharitis.
In conclusion, the combined therapy was superior in decreasing
the D. folliculorum count in all groups and in reducing the mite
count to the normal level in rosacea and in blepharitis lesions,
while the two regimens were comparable in reducing the mite
count to the normal level in acne and peri-oral dermatitis lesions.0
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Figure 2. Mite density of blepharitis group before treatment and through follow up
visits using different regimen therapy.
Table 3
Comparing the percentage of patients with a Demodex density reaching normal levels and patients with a Demodex density higher than the normal level among studied
groups at the last visit, using different therapy regimens
Ivermectin therapy Combined therapy Difference (95% CI) p-Valuea
Acne group 11/15 (73.3%) 15/15 (100%) 0.27 (0.04–0.6) 0.1
Rosacea group 2/15 (13.3%) 14/15 (93.3%) 0.80 (0.4–0.9) <0.001
Peri-oral dermatitis group 13/15 (86.7%) 15/15 (100%) 0.13 (0.1–0.4) 0.5
Blepharitis group 7/15 (46.7%) 15/15 (100%) 0.54 (0.2–0.8) 0.002
CI, conﬁdence interval (by Wilson with continuity correction).
a Chi-square test.
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Figure 3. Mite density of acne group before treatment and through follow up visits
using different regimen therapy.
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Figure 4. Mite density of peri-oral dermatitis group before treatment and through
follow up visits using different regimen therapy.
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